Finance

IVF frozen samples
Business

A new venture fund will invest in reproductive medicine. Here’s what’s worth watching in the field

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Pharmalot

Pharmalittle: FDA approves a record number of generics; Bristol-Myers’ Opdivo fails lung cancer study goal

By Ed Silverman

Pharmalot

Pharmalittle: Brexit fears hurt U.K. clinical trial work; Pfizer readies its new executive team

By Ed Silverman

FDA funding illo
Politics

Questions about funding and purpose loom over a foundation Congress created to help the FDA

By Ike Swetlitz

STAT SPOTLIGHT
Biotech

Startup Spotlight: This Cambridge biotech snagged a deal with Roche without ever making a pitch

By Kate Sheridan

Adam Boehler
Politics

What are ambulances actually chasing?: A conversation with Medicare’s new innovation chief

By Casey Ross

Pharmalot

Pharmalittle: Pfizer CEO Ian Read to step aside; Novo Nordisk cutting 250 jobs in the U.S.

By Ed Silverman

Pharmalot

Bausch settles a ‘channel stuffing’ probe by its Salix subsidiary

By Ed Silverman

Vials
Pharmalot

Pay-to-delay deals for biosimilars may be hard to pull off under a newly passed bill

By Ed Silverman

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Andy Slavitt
Health

Andy Slavitt wants health technology to benefit the disenfranchised. He’s raised $115 million to make it happen

By Casey Ross

STAT Live

Webinar archive: How to interpret clinical trial results like a pro

By Sharon Begley and Adam Feuerstein

Pharmalot

Pharmalittle: AstraZeneca CEO moans about his salary; Amarin fish oil capsule shows dramatic benefits

By Ed Silverman

Generic medicine bottle
Politics

Generic drug makers face ‘a silent crisis,’ FDA official says, and raising prices could help

By Ike Swetlitz

HONG KONG-STOCKS
Biotech

How is Hong Kong’s biotech experiment going? A Hong Kong Stock Exchange official weighs in

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Biotech

Did biotech billionaire Phillip Frost get a raw SEC deal?

By Damian Garde

Dr. Beth Seidenberg
Biotech

Can LA be a new biotech hub? Kleiner Perkins veteran votes yes with a new venture fund

By Meghana Keshavan

The Readout LOUD

LISTEN: Founders’ funds, doctors’ disclosures, and the subtle art of beeping

By Damian Garde, Adam Feuerstein, and Rebecca Robbins

Pharmalot

Pharmalittle: Compounders getting pushback; fast-acting flu drug shows potential

By Elizabeth Cooney

Phillip Frost
Biotech

SEC charges a biotech billionaire with pump-and-dump fraud

By Damian Garde

Medication
First Opinion

Rush to end drug rebates may be bad for patients, payers, and pharma

By Ian D. Spatz

Jackie Fouse
Business

Agios Pharma names a new CEO, one with commercial chops in biotech

By Adam Feuerstein

Pharmalot

Sanofi pays $25 million to settle charges of bribing doctors and officials in the Mideast

By Ed Silverman

Pharmalot

Pharmalittle: Biotech boom pays off for Wall Street analysts; Canadian province sues opioid makers

By Ed Silverman

Pharmalot

Pharmalittle: Emergent buys Narcan but promises to maintain pricing; Novartis vows Alcon spin off on track despite a recall

By Ed Silverman

Kendall Square
Biotech

The IPO boom has been particularly kind to biotech in Massachusetts

By Jonathan Saltzman — Boston Globe and Kate Sheridan — STAT

Greg Yap
Biotech

Don’t say ‘disrupt’ and other red flags when pitching to a venture capitalist

By Rebecca Robbins and Damian Garde

D.C. Insight IMAGE
Opinions Plus

Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros

By Elizabeth Cooney

Menstrual pad pattern
Biotech

At Silicon Valley’s debutante ball for startups, there’s more biology than ever

By Rebecca Robbins

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy